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Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, USA
Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent of Kaposi sarcoma (KS)
and certain rare B cell lymphoproliferative disorders. KSHV infection of endothelial
cells (EC) in vitro increases expression of the inducible host-encoded enzyme heme
oxygenase-1 (HO-1), which is also strongly expressed in KS tumors. HO-1 catalyzes the
rate-limiting step in the conversion of heme into iron, biliverdin and the gasotransmitter
carbon monoxide (CO), all of which share anti-apoptotic, anti-inflammatory, pro-survival,
and tumorigenic activities. Our previous work has shown that HO-1 expression in
KSHV-infected EC is characterized by a rapid yet transient induction at early times
post-infection, followed by a sustained upregulation co-incident with establishment of
viral latency. These two phases of expression are independently regulated, suggesting
distinct roles for HO-1 in the virus life cycle. Here, we investigated the role of HO-1
during acute infection, prior to the onset of viral gene expression. The early infection
phase involves a series of events that culminate in delivery of the viral genome to the
nucleus. Primary infection also leads to activation of host innate immune effectors,
including the pattern recognition receptor TLR4, to induce an antiviral response. It
has been shown that TLR4-deficient EC are more susceptible to KSHV infection than
wild-type controls, suggesting an important inhibitory role for TLR4 in the KSHV life
cycle. TLR4 signaling is in turn subject to regulation by several virus-encoded immune
evasion factors. In this report we identify HO-1 as a host protein co-opted by KSHV
as part of a rapid immune evasion strategy. Specifically, we show that early HO-1
induction by KSHV results in increased levels of endogenous CO, which functions as
a TLR4 signaling inhibitor. In addition, we show that CO-mediated inhibition of TLR4
signaling leads to reduced expression of TLR4-induced antiviral genes, thus dampening
the host antiviral response and facilitating KSHV infection. Conversely, inhibition of HO-1
activity decreases intracellular CO, enhances the host antiviral response and inhibits
KSHV infection. In conclusion, this study identifies HO-1 as a novel innate immune
evasion factor in the context of KSHV infection and supports HO-1 inhibition as a viable
therapeutic strategy for KS.
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INTRODUCTION
Kaposi sarcoma herpesvirus (KSHV), a tumorigenic human
gamma-2 herpesvirus, is the etiologic agent of Kaposi sarcoma
(KS) (Moore and Chang, 1998) and the lymphoproliferative
disorders known as primary effusion lymphoma (PEL) and
plasmablastic multicentric Castleman disease (MCD) (Moore
and Chang, 1998; Cesarman and Mesri, 2007). KSHV infection
of lymphatic endothelial cells (LEC) in vitro results in induction
of the stress-inducible host enzyme heme oxygenase-1 (HO-1).
KS spindle cells in biopsy tissue also strongly express HO-1,
suggesting that the enzyme may play a role in tumorigenesis,
as has been shown for HO-1 in other cancers (McAllister
et al., 2004; Chau, 2015). In vitro, KSHV induction of HO-
1 occurs in two distinct phases, a transient phase upon acute
infection and a sustained phase coincident with the establishment
of viral latency. The initial phase of HO-1 upregulation is
independent of de novo viral gene expression, suggesting that
virion components contribute to initial induction (Botto et al.,
2015). This observation is supported by an independent study
demonstrating induction of HO-1 early post KSHV infection
via an NRF2-dependent mechanism in response to infection-
associated oxidative stress (Gjyshi et al., 2014).
Heme oxygenase-1 enzymatic activity catalyzes the
degradation of heme into carbon monoxide (CO), ferrous
iron, and biliverdin, which is subsequently converted to bilirubin
(Ryter and Choi, 2009). HO-1 is ubiquitously expressed, albeit at
low levels in most cell types, but is rapidly induced in response to
diverse cellular stressors, as well as being strongly expressed in
several types of cancer (Ryter and Choi, 2015). HO-1 is thought
to contribute to cytoprotection and proliferation through the
catabolism of heme, a pro-oxidant molecule that is cytotoxic
in excess, into metabolites with anti-oxidant, pro-angiogenic,
anti-apoptotic, and anti-inflammatory activities (Ryter and
Tyrrell, 2000; Ryter et al., 2006; Ryter and Choi, 2009). Of
particular relevance to the current study, the endogenous
gasotransmitter CO participates in intracellular signaling
pathways that culminate in anti-inflammatory, anti-coagulative
and pro-survival outcomes (Liu et al., 2002; Pae et al., 2004;
Otterbein et al., 2005; Nakahira et al., 2006; Ryter and Choi,
2009; Ruan et al., 2014; Yang et al., 2014; Xue and Habtezion,
2014; Riquelme et al., 2015). The discovery of compounds
categorized as “carbon monoxide releasing molecules” (CORM)
has allowed for further mechanistic insight into the role of CO
in biological systems (Ryter and Choi, 2015). Interestingly, CO
is able to inhibit innate immune responses and in particular
to block TLR4 signaling by preventing the interaction between
TLR4 and its adaptor proteins MyD88 and TRIF (Nakahira et al.,
2006; Wang et al., 2009; Chi et al., 2014). This down-modulatory
effect reveals an important anti-inflammatory role for CO in
pathogen-exposed cells and suggests that CO could contribute
to immune evasion by pathogens such as KSHV that induce
HO-1. Innate immunity represents the first layer of host defense
against pathogens, and appropriate sensing of non-self is critical
for initiating an effective immune response (O’Neill et al., 2013).
Early responses to microbial pathogens are typically initiated by a
class of immune sensors known as pattern recognition receptors
(PRRs). The Toll-like receptors (TLRs) are a subclass of PRRs
that detect a broad range of pathogens (Boehme and Compton,
2004). KSHV activates multiple TLRs including TLR9, which
recognizes unmethylated CpG motifs of double-stranded DNA
(dsDNA) (West et al., 2011), TLR3, which senses virus replication
intermediates such as dsRNA (West and Damania, 2008) and
TLR4, which is most well-known for recognizing Gram-negative
bacterial lipopolysaccharide (LPS) (Lagos et al., 2008). The
significance of the balance between KSHV and host immunity is
underscored by the increased development of KSHV-associated
malignancies in the setting of immunodeficiency (Feng et al.,
2013). Viruses adopt a variety of mechanisms to evade the
host immune response, and KSHV encodes several proteins
and micro-RNAs that target critical host components of both
the innate and the adaptive immune system (Feng et al., 2013;
Brulois and Jung, 2014). Although the KSHV component(s)
that activate TLR4 signaling remain to be identified, UV-
inactivated KSHV induces TLR4 signaling, suggesting that one
or more viral glycoproteins are responsible (Lagos et al., 2008).
Downregulation of TLR4 in endothelial cells, the precursors of
KS tumor cells, leads to an enhanced susceptibility to KSHV
infection (Lagos et al., 2008), suggesting an important role for
this receptor in the regulation of endothelial infection.
In the present study, we have explored the role of CO,
a gasotransmitter endogenously generated by the enzymatic
activity of HO-1, in modulating TLR4 signaling during de novo
KSHV infection of endothelial cells, via the use of an intracellular
CO sensor and a small molecule inhibitor of HO-1 activity. We
find that intracellular CO levels are enhanced by KSHV infection
and that CO is capable of inhibiting TLR4 signaling to promote
KSHV infection.
MATERIALS AND METHODS
Cells and Viruses
Primary adult human LEC were obtained from Lonza (Allendale,
NJ, USA). Immortalized LEC (iLEC) were generated from
primary LEC via transduction with a retroviral vector expressing
HPV16 E6/E7, as previously described (Moses et al., 1999;
McAllister and Moses, 2007). iLEC were cultured in EGM-2
prepared by supplementing basal medium (EBM-2; Lonza)
with 10% fetal bovine serum (FBS), penicillin-streptomycin–L-
glutamine (PSG; HyClone, Logan, UT, USA), and additional EC
growth supplements (EGM-2MV Bullet kit; Lonza). HeLa cells
were cultured in DMEM with 10% FBS and PSG. The epithelial
iSLK cell line (generously provided by Dr. Rolf Renne, University
of Florida, Gainesville, FL, USA with the kind permission of Dr.
Jae Jung, University of Southern California, Los Angeles, CA,
USA and Dr. Don Ganem, Novartis Institutes for BioMedical
Research) was used to produce stocks of recombinant KSHV.
iSLK cells were grown in DMEM supplemented with 10%
FBS, PSG, puromycin (1 µg/ml), neomycin (200 µg/ml), and
hygromycin (1.5 mg/ml). The recombinant KSHV BAC clone
BAC16, derived from rKSHV.219 and kindly provided by Dr.
Jung, was used in all KSHV infection experiments (Brulois
et al., 2012). To produce stocks of KSHV-BAC16, iSLK cells
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harboring the BAC16 genome were treated with doxycycline
(1 µM) and sodium butyrate (3 mM) for 72 h. Supernatants were
then collected, clarified by low-speed centrifugation, transferred
to ultracentrifuge tubes, underlaid with 25% sucrose in TNE
(150 mM NaCl, 10 mM Tris [pH 8.0], 2 mM EDTA [pH 8.0])
and then centrifuged at 78,000 × g for 2 h at 4◦C. The
supernatants were disposed of and the remaining virion pellets
were resuspended in TNE. Stocks of KSHV-BAC16 were titrated
by first infecting iLEC with serially diluted virus preparations.
After 48 h, the cells were harvested and evaluated for GFP
expression via flow cytometry. All de novo infections were
conducted using an MOI that results in 80% GFP-expressing
iLEC 48 h after infection.
Antibodies and Other Reagents
A rabbit anti-KSHV ORF65 antibody (generously provided by
Dr. Bala Chandran, Rosalind Franklin University of Medicine
and Science, Chicago, IL, USA) was diluted 1:1000 and used
to detect the viral capsid by immunofluorescence (IFA) in
combination with an Alexa Fluor 488-conjugated anti-rabbit
secondary antibody (1:1000, Invitrogen, Eugene, OR, USA).
Rhodamine phalloidin (Invitrogen, Eugene, OR, USA) was
diluted 1:40 to detect actin filaments via IFA. An anti-HO-1
antibody (BD Transduction Laboratories, San Jose, CA, USA)
and an anti-β-actin-HRP conjugated antibody (Sigma, St. Louis,
MO, USA) were used in western blot procedures at a dilution
of 1:1,000 and 1:20,000, respectively. An anti-mouse-HRP
conjugated antibody (EMD Millipore, Billerica MA, USA) was
used at a dilution of 1:10,000 as the secondary antibody for
HO-1 detection. LPS at 100 ng/ml was used to induce TLR4
signaling. The TLR4 inhibitor CLI-095 (Invivogen) was used at
a concentration of 3 µM. The HO-1 inhibitor OB-24 (Alaoui-
Jamali et al., 2009) was kindly provided by Dr. Ajay Gupta (Osta
Biotechnologies, Inc., Dollard-des-Ormeaux, QC, Canada) and
was used at a concentration of 20 µM. The viral DNA polymerase
inhibitor Foscarnet (FOS, Sigma) was used at a concentration
of 400 µM. The CO releasing molecule CORM-2 (Sigma) was
used at a concentration of 10 µM. Bilirubin (Sigma) was used at
20 µM. Ferric citrate (Sigma) was used at 20 µM. Bilirubin and
ferric citrate were used in conjunction with CORM-2 in order
to evaluate both their collective and individual contributions to
TLR4-signaling in LPS-treated iLEC. The HO-1 substrate heme
arginate (HA) was obtained from Orphan Europe (Nanterre,
France) and used at 5 µM. When CORM-2 was used, DMSO
was included as a vehicle control treatment. Where appropriate,
PBS was used as a vehicle control for HA and OB-24, which are
water-soluble compounds.
Immunofluorescence and Image Analysis
For IFA experiments, cells were seeded onto collagen-coated
coverslips (BD Biosystems, Franklin Lakes, NJ, USA) in six-well
tissue culture plates. At the end of an experiment, the cells were
fixed in 2% paraformaldehyde for 8 min, washed three times
in phosphate-buffered saline (PBS), and permeabilized in 0.25%
Triton X-100 for 8 min. Samples were next blocked [20% normal
goat serum (NGS) in PBS] for 20 min at 37◦C and then incubated
with primary antibody in PBS with 1% NGS for 1 h at 37◦C.
Coverslips were then washed three times in PBS and incubated
with a combination of the appropriate secondary antibody,
rhodamine phalloidin for actin filament staining, and the
nuclear stain 4,6-diamidino-2-phenylindole (DAPI) for 45 min
at 37◦C. Coverslips were then washed three times in PBS and
mounted on glass slides with Fluoromount-G (Southern Biotech,
Birmingham, AL, USA). Prepared slides were analyzed with
a DeltaVision real-time deconvolution fluorescence microscope
(Applied Precision, Issaquah, WA, USA), and images were
captured with a Photometrics CoolSNAP HQ camera. Image
analysis was performed with SoftWoRx (Applied Precision).
Stacks of images (0.2-µm z-step) were captured at 60×
magnification. Stacks were subjected to deconvolution, and
two- or three-section projections were made by superimposing
representative z-planes to generate the final images.
Carbon Monoxide Sensor
A plasmid construct expressing the fluorescent CO sensor protein
COSer was kindly provided by Dr. Chuan He (University
of Chicago, Chicago, IL, USA). COSer is a cpVenus-CooA
fusion protein that fluoresces in the presence of CO (Wang
et al., 2012). The cpVenus moiety is a circularly permuted
YFP variant, while CooA is a CO-sensing protein produced
by Rhodospirillum rubrum. The gene encoding COSer was
subcloned into the lentiviral vector pCDH-CMV-MCS-EF1-
Puro (System Biosciences, Palo Alto, CA, USA) using standard
methods. Lentiviral particles derived from the resulting pCDH-
COSer construct were then used to generate a stable HeLa cell
line expressing the CO sensor (HeLa-COSer). HeLa-COSer cells
were then used as a tractable system with which to measure
endogenous CO in response to specific stimuli. Flow cytometry
for cpVenus fluorescence was then used to assess intracellular
CO levels in HeLa-COSer cells subjected to various experimental
conditions.
Reverse Transcription-qPCR
Extraction of total RNA was performed using RNeasy minikits
(Qiagen, Valencia, CA, USA). A DNase I (Qiagen) digestion
step was included to eliminate any residual DNA. Total cDNA
was generated from these samples with the SuperScript III
First-Strand Synthesis System (Invitrogen; Life Technologies,
Carlsbad, CA, USA). The following gene-specific primers were
used for qPCR assays: GAPDH F, 5′-GAAGGTGAAGGTCGG
AGT-3′; GAPDH R, 5′-GAAGATGGTGATGGGATTTC-3′;
HO-1 F, 5′-GCCCTTCAGCATCCTCAGTTC-3′; HO-1 R, 5′-G
GTTTGAGACAGCTGCCACA-3′; ORF59 F 5′-CGAGTCTTCG
CAAAAGGTTC-3′; ORF59 R, 5′-AAGG GACCAACTGGTGT
GAG-3′; IL-1β F 5′-GCCAATCTTCATTGCTCAAGTGT-3′,
IL-1β R 5′-AGCCATCATTTCACTGGCGA-3′; LANA-1 F 5′-
CGCGAATACCGCTATGTAC-3′, LANA1 R 5′-CTGGAAGG
CCTGAGATAA-3′; K5 F 5′-ACAAGGACCGTCAATTCG
ATG-3′, K5 R 5′-TGCCATACCGACGGCC-3′; IL-6 F 5′- CCAG
GAGCCCAGCTATGAAC-3′, IL-6 R 5′-CCCAGGGAGAAGGC
AACTG-3′; IFNβ F 5′-ACGCCGCATTGACCATCTA-3′, IFNβ
R 5′-TAGTCTCATTCCAGCCAGTGC-3′. Nuclear and
cytoplasmic fractionations were performed using the Nuclei
EZ Prep Kit (Sigma), and the resulting fractions were then
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subjected to DNA extraction using the Blood and Tissue DNA kit
(Qiagen). For detection of genomic targets, the following primers
were used: ORF26 F 5′-ACGCGAAAGGATTCCACCAT-3′,
ORF26 R 5′-TCCGTGTTGTCTACGTCCA-3′; GAPDH F
5′-TGCCTTCTTGCCTCTTGTCTCT-3′, GAPDH R 5′-GGCT
CACCATGTAGCACTACC-3′ (nuclear marker); MT-ND1 F
5′-CGGAGTAATCCAGGTCGGTT-3′ MT-ND1 R 5′-AGGCG
CTTTGTGAAGTAGGC-3′ (cytoplasmic marker). For qPCR
assays, 5 µl of cDNA or DNA (typically 10 ng) was mixed with
gene specific primers plus 12.5 µl of Power SYBR Green PCR
Master Mix (ABI, Foster City, CA, USA) in a final volume of
25 µl. Optimization of primer and sample concentrations was
performed for all targets. For qPCR assays, standard curves were
established using appropriate control samples and a dilution
series ranging from 100 ng to 3.2 pg of cDNA/DNA. Sample
amplification was performed in an ABI real-time PCR 7500
system. For relative quantitation experiments, the signal for each
cDNA was normalized to GAPDH cDNA levels. KSHV genome
copy numbers were normalized to host genome copies (GAPDH)
and are displayed as either viral genome copies per 100 ng of
DNA or viral genomes per host genome at 2 h post-infection.
Flow Cytometric Analysis
Cells to be analyzed via flow cytometry were first dissociated
from tissue culture plates using non-enzymatic Cellstripper
(25-056-CI; CellGro/Corning, Manassas, VA, USA) and then
pelleted at 1800 × g at 4◦C for 5 min. The cells were then fixed
using 2% PFA, incubated on ice for 15 min, pelleted, washed twice
in 1X Washing Buffer (1X PBS, 2% NGS, 0.1% sodium azide),
resuspended in 1X Washing Buffer and finally analyzed on an
LSR2 Flow Cytometer (BD Biosciences, San Diego, CA, USA).
Western Blotting
Cells were lysed in radio immunoprecipitation assay buffer
(50 mm Tris [pH 7.5], 150 mm NaCl, 1% Nonidet P-40,
0.5% deoxycholate, 0.1% SDS, 1x Complete Protease Inhibitor
[Roche Applied Science, Pleasanton, CA, USA] and Phosphatase
inhibitors), incubated on ice for 30 min, and then centrifuged
at 13,400 × g for 10 min at 4◦C. Cleared supernatants were
transferred to fresh tubes, and protein concentrations were
determined via a bicinchoninic acid (BCA) assay (Thermo Fisher
Scientific, Waltham, MA, USA). Proteins were separated via
reducing SDS-PAGE, transferred to polyvinylidene difluoride
membranes, incubated in blocking buffer (5% Bovine Serum
Albumin in Tris-buffered saline with 0.1% Tween 20 [TBST])
for 1 h, and then probed with the appropriate primary antibody
diluted in blocking buffer. Blots were then washed three times
with TBST, incubated with the appropriate secondary antibodies
in blocking buffer, and then washed a further three times with
TBST. Blots were developed with ECL western blotting substrate
(Thermo Fisher Scientific), and the resulting data were captured
with G:BOX (Syngene, Frederick, MD, USA). The images shown
are representative of two independent experiments.
Bilirubin ELISA
Intracellular bilirubin levels were detected using a human total
bilirubin (TBIL) ELISA Kit (MyBiosource, San Diego, CA,
USA). The TBIL ELISA is compatible for use with cell lysates
and, by measuring the heme metabolite bilirubin, provides
a functionally equivalent readout of HO-1 enzyme activity.
Procedures followed were as described in the manufacturer’s
manual. Briefly, standards and test samples were incubated with
anti-bilirubin HRP-conjugated antibody in pre-coated plates for
1 h. Wells were then washed three times and incubated with the
substrate. After addition of a stop solution, plates were read at
450 nm in a microplate reader.
Statistical Analysis
Quantitative PCR data is expressed as the mean± Standard Error
of the Mean (SEM). One-way ANOVA was used to compare
means from different groups.
RESULTS
KSHV Infection Enhances the Production
of Intracellular CO to Reduce Production
of TLR-4-Activated Antiviral Cytokines
We previously demonstrated that de novo infection of iLEC with
KSHV induces expression of the host enzyme HO-1 with an early,
transient phase followed by a sustained phase associated with the
establishment of latency (Botto et al., 2015). In the current study,
we sought to investigate if the early phase of HO-1 induction
plays a role in KSHV infection. We began by validating our
prior observations (Botto et al., 2015), reconfirming that KSHV-
infected iLEC exhibit a transient peak of HO-1 message between
4 and 6 h post-infection (hpi) and that this early HO-1 induction
is observed regardless of whether the viral inoculum is live- or
UV-inactivated (Figure 1A).
Since HO-1 catabolizes heme into CO, free iron, and
biliverdin, which is then rapidly reduced to bilirubin by biliverdin
reductase, we considered the possibility that any or all of these
biologically active metabolites could influence the viral infection
process. We were particularly interested in the gasotransmitter
CO, as CO has been shown to inhibit activation of LPS-induced
TLR4 (Wang et al., 2009) while TLR4 has been identified as a
pathogen sensor mediating innate immunity to KSHV (Lagos
et al., 2008). To evaluate the influence of HO-1 metabolites
on TLR4 activation, iLEC were pretreated with DMSO vehicle,
bilirubin (BR), CO-releasing molecule (CORM-2), Ferric citrate
(Fe) or the TLR4 inhibitor CLI-095 for the times indicated and
then stimulated with LPS or DMSO alone for another 4 h.
Expression of the inflammatory cytokines IL-1β (Figure 1B) and
IFNβ (Supplementary Figure S1) was then measured by qPCR
as a readout of TLR4 activation. This experiment revealed that
CO was the only heme metabolite able to block TLR4-signaling
in LPS-treated iLEC. Specifically, iLEC treated with exogenous
CO produced significantly reduced levels of IL-1β and IFNβ in
response to LPS stimulation relative to cells treated with vehicle
alone. The ability of the TLR4 inhibitor CLI-095 to similarly block
cytokine production in response to LPS stimulation supported
the TLR4-specificity of CO-mediated inhibition. Conversely,
iLEC treated with the other heme metabolites (Fe and to a
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FIGURE 1 | Kaposi sarcoma herpesvirus (KSHV) infected endothelial cells produce carbon monoxide (CO) which reduces production of TLR4-derived
cytokines. (A) qPCR for heme oxygenase-1 (HO-1) message in iLEC infected with live KSHV-BAC16 (live, dark gray) or UV-inactivated KSHV-BAC16 (UV, light gray)
at different times post-infection. Data are expressed as the mean ± SEM (n = 3). (B) qPCR for IL-1β message in iLEC pretreated for 2 h with DMSO (Vehicle), 20 µM
Bilirubin (BR), 20 µM Ferric citrate (Fe), or 3 µM TLR4 inhibitor (CLI-095) or for 10 min with 10 µM CORM-2 and then stimulated with 100 ng/ml LPS for 4 h (light
gray) or DMSO (dark gray) as a vehicle control. Data are expressed as the mean ± SEM (n = 3). (C) Flow cytometric analysis of HeLa-COSer cells treated with
DMSO control (vehicle), 10 µM CORM-2 or 5 µM heme arginate (HA). Shown is the percentage of YFP positive cells at the time of peak CO production; 20 min for
CORM-2 and 4 h for HA or vehicle. Data are expressed as the mean ± SEM (n = 3). (D) Flow cytometric analysis of HeLa-COSer cells that were mock-infected (dark
gray) or KSHV-infected (light gray) and collected at early times (0–8 hpi) post-infection. CO production is measured by quantitation of the percentage of YFP positive
cells. Data are expressed as the mean ± SEM (n = 3). (E) Western blot for HO-1 protein expression in HeLa-COSer cells infected with KSHV for 2, 4, 6, and 8 h.
β-actin was used as the loading control. Data are representative of two independent experiments (n = 2). (F) qPCR for IL-1β message in iLEC infected with live
KSHV-BAC16 (live, dark gray) or UV-inactivated KSHV-BAC16 (UV, light gray) at different times post-infection. Data are expressed as the mean ± SEM (n = 3).
(G) qPCR for IL-1β message in iLEC pretreated with DMSO control (dark gray) or 10 µM CORM-2 (light gray) for 10 min and then infected with KSHV-BAC16. Data
are expressed as the mean ± SEM (n = 3). ∗p-value ≤ 0.05, ∗∗p-value ≤ 0.01. A one-way ANOVA test was used for statistical analysis.
lesser extent BR) remained responsive to TLR4 activation. These
experiments also verified that HO-1 message levels were not
significantly altered by LPS stimulation, but were moderately
induced by CORM-2, the latter likely reflecting the cytoprotective
potential of CO (Supplementary Figure S2).
The above experiments confirmed that exogenous CO (via
CORM-2) can inhibit TLR4 signaling. We next asked whether
KSHV-induced HO-1 was able to raise endogenous CO to similar
levels. In order to detect endogenous CO, we employed the
fluorescent CO sensor COSer (Wang et al., 2012). We first
generated a stable HeLa cell line (HeLa-COSer) expressing COSer
and tested it for induction of fluorescence in the presence of either
CORM-2 or heme arginate (HA), the latter of which is both an
inducer and a substrate for HO-1. As expected, HeLa-COSer cells
exposed to either CORM-2 or HA showed a significant increase
in the percentage of YFP positive cells compared to DMSO-
treated controls (Figure 1C). The time difference for peak of
CO production (20 min for CORM-2 and 4 h for HA) likely
reflects the fact that CORM-2 functions to deliver exogenous
CO, while endogenous CO produced as a downstream metabolite
of HA requires HO-1 enzyme activity. Having validated the
HeLa-COSer system as a means to measure temporal increases in
endogenous CO, we next evaluated the effect of KSHV infection
on endogenous CO levels over the intervals post-infection that
spanned the duration of KSHV-triggered early HO-1 induction
(Figure 1D). Importantly, YFP fluorescence was significantly
enhanced in HeLA-COSer cells infected with KSHV, at a time
coincident with the kinetics of early HO-1 induction observed
in KSHV-infected iLEC (Figure 1E). Taken together, these data
suggest that early KSHV induction of HO-1 is indeed sufficient
to raise levels of intracellular CO.
Having demonstrated (Figure 1B and Supplementary
Figure S1) that IL-1β and IFNβ expression can be used to
measure LPS-dependent TLR4 signaling, we next used these
parameters to test the KSHV-dependent induction of TLR4
signaling at the times co-incident with early HO-1 induction. As
shown in Figure 1F, levels of IL-1β message in cells infected with
both live and UV-inactivated virus were increased as early as
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2 hpi (Figure 1F). By 4 hpi, IL-1β transcription was sustained in
cells infected with UV-inactivated KSHV, but decreased in cells
infected with live virus, likely due to de novo expression of viral
immune evasion proteins. Because CO is able to inhibit TLR4
signaling (Figure 1B) and because KSHV infection activates
TLR4 signaling (Lagos et al., 2008), we next tested whether the
expression of IL-1β and IFNβ in KSHV-infected iLEC could be
reduced by delivering CO to iLEC immediately prior to infection.
Indeed, iLEC pretreated with CORM-2 and then infected with
KSHV showed significantly lower levels of IL-1β compared
to control cells [Figure 1G; similar trends were observed for
IFNβ (dns)], indicating that CO is able to block TLR4 signaling
and reduce the production of antiviral cytokines in response to
KSHV infection.
TLR4 Inhibition via CO or a TLR4
Inhibitor Facilitates KSHV Infection of
iLEC
Innate immune activation in response to viral challenge is
important for the induction of interferon-stimulated genes
(ISGs), the products of which target all steps of the infection
(Schoggins and Rice, 2011). Since CO treatment of iLEC led to
a reduction in the KSHV-dependent production of the antiviral
cytokines IL-1β and IFNβ, we next determined whether this same
treatment had any impact on the ability of KSHV to infect iLEC.
Indeed raising CO levels via CORM-2 treatment of cells prior
to KSHV infection resulted in a modest but significant increase
in the number of viral genomes (Figure 2A) and the early viral
transcript K5 (Figure 2B) detected at early times (2, 4, and 6 h)
post-infection. As expected, a similar phenotype was observed in
iLEC treated with the TLR4 inhibitor CLI-095 prior to KSHV
infection (Figure 2C). To confirm that TLR4 inhibition does
indeed facilitate KSHV infection, iLEC pretreated with CLI-095
were evaluated for GFP expression via flow cytometry 24 h after
infection with KSHV-BAC16. Again, pretreatment of iLEC with
the TLR4 inhibitor resulted in detection of a significantly higher
percentage of KSHV-infected (GFP positive) cells as compared to
cells treated with a vehicle (DMSO) control (Figure 2D). Further
support for this notion was provided via siRNA-dependent
knockdown of TLR expression, which resulted in the reduced
expression of the antiviral cytokine IFNβ as well as the enhanced
expression of the KSHV lytic marker gB (Figures 2E,F). Note
that CLI-095 treatment of iLEC did not significantly impact HO-1
expression, indicating that any effect observed with this inhibitor
was attributable to its effect on TLR4, and not to non-specific
modulation of HO-1 (Supplementary Figure S3). Together, these
data suggest that TLR4 inhibition, whether achieved through CO
treatment or chemical inhibition, renders iLEC more permissive
to KSHV infection.
Inhibition of HO-1 Activity in iLEC
Results in Decreased CO Production and
Reduced KSHV Infection
As shown above, KSHV infection of HeLaCOSer cells leads
to both HO-1 induction (Figure 1E) and CO generation
(Figure 1D) at early times post-infection. Our next goal was to
directly link CO production with HO-1 activity. For this purpose,
we employed the HO-1 inhibitor OB-24, an imidazole-based
water-soluble small-molecule inhibitor that has demonstrated
potent anti-tumor and anti-metastatic activity in preclinical
tumor models (Alaoui-Jamali et al., 2009). Contrary to other
commonly used HO-1 inhibitors, OB-24 selectively inhibits
HO-1 enzyme activity and does not influence HO-1 protein
expression (Kinobe et al., 2008). For the first of these experiments,
HeLa-COSer cells were pretreated overnight with OB-24 or
vehicle and then exposed to the HO-1 inducer and substrate
HA. As expected, HA treatment alone led to a significant
increase in CO production as measured by YFP fluorescence,
while pre-treatment of the cells with OB-24 largely blocked
this production, demonstrating the correlation between HO-1
activity and CO production (Figure 3A). Next, HeLa-COSer cells
pretreated overnight with OB-24 or PBS vehicle were infected
with KSHV, harvested at early intervals (2–6 hpi) and analyzed for
YFP fluorescence. Importantly, YFP expression was significantly
reduced in KSHV-infected HeLa-COSer cells pretreated with
OB-24 as compared to vehicle-treated cells (Figure 3B). These
data demonstrate that KSHV-induced HO-1 does indeed lead to
elevation of endogenous CO.
We next performed similar experiments in endothelial cells.
We initially established a non-toxic but effective dose-range for
OB-24 by staining iLEC for the apoptotic markers Annexin V
and propidium iodide (Supplementary Figure S4). With this value
established, OB-24 was then tested for its capacity to inhibit
HO-1 activity in KSHV-infected iLEC, as well as its potential to
affect the host antiviral response and impact KSHV infection.
Accordingly, iLEC were pretreated overnight with Vehicle (PBS)
or OB-24. The next day, the cells were infected with KSHV,
harvested at intervals spanning the early HO-1 induction peak
(2–8 hpi) and then evaluated for bilirubin generation (Rücker
and Amslinger, 2015) (Figure 3C), IFNβ expression (Figure 3D)
and viral genome production (Figure 3E). As expected, treatment
of iLEC with OB-24 abolished the peak of HO-1 activity that
occurs following de novo KSHV infection, and this reduced
activity correlated with both increased levels of IFNβ transcripts
and reduced viral genome copy numbers. When iLEC pretreated
with OB-24 and infected with KSHV for 24 hpi were analyzed,
inhibition of HO-1 activity was maintained (Figure 3F) and
cells expressed significantly lower levels of representative lytic
(ORF59; Figure 3G) and latent (LANA-1; Figure 3H) viral
transcripts. Thus, the data obtained using chemical inhibition
of HO-1 activity further support the hypothesis that inhibition
of HO-1 activity in iLEC increases the potency of the antiviral
response and reduces the efficiency of de novo KSHV infection.
TLR4 Inhibition Influences a Step in the
Infection Process Subsequent to Virus
Binding, Entry and Genome Delivery to
the Nucleus
As illustrated in Figures 1, 2, TLR4 inhibition with either CLI-095
or CORM-2 renders iLEC more permissive to KSHV infection.
To determine which step of the de novo infection process was
affected, the various stages of the KSHV infection process were
Frontiers in Microbiology | www.frontiersin.org 6 April 2017 | Volume 8 | Article 568
fmicb-08-00568 March 30, 2017 Time: 13:59 # 7
Botto et al. HO-1 Metabolite Promotes KSHV Infection
FIGURE 2 | TLR4 inhibition via CO or TLR4 inhibitor CLI-095 facilitates KSHV infection of iLEC. (A) qPCR for KSHV genome copies in iLEC pretreated with
DMSO control (dark gray) or 10 µM CORM-2 (light gray) for 10 min and then infected with KSHV-BAC16. KSHV genome copies are represented as relative to the
number of genomes present at 2 hpi. Data are expressed as the mean ± SEM (n = 3). (B) qPCR for KSHV K5 transcript in iLEC pretreated with DMSO control (dark
gray) or 10 µM CORM-2 (light gray) for 10 min and then infected with KSHV-BAC16. KSHV K5 levels are represented as relative to K5 levels measured at 2 hpi. Data
are expressed as the mean ± SEM (n = 3). (C) qPCR for KSHV genome copies in iLEC pretreated with DMSO control (dark gray) or 3 µM CLI-095 (light gray) and
then infected with KSHV-BAC16. KSHV genome copies are represented as relative to the number of genomes present at 2 hpi. Data are expressed as the
mean ± SEM (n = 3). (D) Flow cytometry for iLEC pretreated with DMSO (Vehicle) or 3 µM TLR4-inhibitor (CLI-095) and then infected with KSHV-BAC16. Infection is
quantified by determining the percentage of GFP positive cells present at 24 hpi. Data are expressed as the mean ± SEM (n = 3). qPCR for IFNβ (E) and gB (F)
message levels in iLEC transfected overnight with Control siRNA (dark gray) or TLR4 siRNA (light gray) and then infected with KSHV for 2, 4, and 6 h. LPS
(100 ng/ml for 4 h) was used as a control stimulus for TLR4 activation. Data are expressed as the mean ± SEM (n = 3). A one-way ANOVA test was used for
statistical analysis. ∗p-value ≤ 0.05, ∗∗p-value ≤ 0.01.
evaluated. iLEC were first treated with a vehicle control (DMSO),
CORM-2 or CLI-095 for the indicated times, then infected with
KSHV at 4◦C, in order to permit virus binding but not entry into
the host cell. After 30 min at 4◦C, cells were either collected to
determine the number of bound virions or further incubated at
37◦C for 60, 90, or 120 min to allow for virus entry and nuclear
trafficking. In order to ensure detection of only intracellular virus
at these later time points, surface-bound virions were removed by
washing the cells with citrate buffer (pH= 3.0) prior to collection.
In order to assess viral genome delivery to the nucleus, infected
iLEC were subjected to nuclear-cytoplasmic fractionation, and
DNA was then extracted from the two fractions. Subsequent
quantitation of KSHV genome copies via qPCR showed that
neither CO nor CLI-095 treatment impacted the number of viral
genomes able to enter the cell (Figure 4A) or reach the nucleus
(Figure 4B). In a parallel approach to confirm this result, KSHV
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FIGURE 3 | Heme oxygenase-1 inhibition results in decreased KSHV infection in iLEC and CO production. (A) Flow cytometric analysis of HeLa-COSer
cells pretreated overnight with PBS control (Vehicle) or 20 µM HO-1 inhibitor OB-24 (OB-24) and then stimulated with PBS (Vehicle; dark gray) or 5 µM heme
arginate (HA; light gray) for 4 h. CO production is measured by percentage of YFP positive cells. Data are expressed as the mean ± SEM (n = 3). (B) Flow cytometry
for HeLa-COSer cells pretreated with PBS vehicle (dark gray) or 20 µM of the HO-1 enzyme activity inhibitor OB-24 (light gray) overnight and then infected with
KSHV. CO production is measured by quantitation of the percentage of YFP positive cells. Data are expressed as the mean ± SEM (n = 3). (C) ELISA for intracellular
bilirubin levels as a measure of HO-1 activity. iLEC were pre-treated with PBS (Vehicle; dark gray) or 20 µM OB-24 (light gray) overnight, infected with KSHV-BAC16
and then harvested for analysis at different times post-infection (2, 4, 6, and 8 hpi). Data are expressed as the mean ± SEM (n = 2). (D,E) qPCR for IL-1β mRNA (D)
and KSHV genome copies (E) in iLEC pretreated overnight with PBS (Vehicle, dark gray) or 20 µM OB-24 (OB24; light gray), infected with KSHV-BAC16 and
harvested for analysis at 2, 4, 6, and 8 hpi. Data are expressed as the mean ± SEM (n = 3). KSHV genome copies are represented as relative to the number of
genomes present at 2 hpi. (F) ELISA for intracellular bilirubin levels in iLEC pretreated with PBS (Vehicle; dark gray) or 20 µM OB-24 (light gray) overnight and then
infected with KSHV for 24 h before harvest and analysis. Data are expressed as the mean ± SEM (n = 2). (G,H) qPCR for KSHV lytic transcript ORF59 (G) and latent
transcript LANA-1 (H) in iLEC pretreated overnight with PBS (Vehicle; dark gray) or with OB-24 at 20 µM or 50 µM (light gray) and then infected with KSHV-BAC16
for 24 h before harvest and analysis. KSHV transcript levels are represented as relative to transcript levels measured at 2 hpi. Data are expressed as the
mean ± SEM (n = 3). ∗p-value ≤ 0.05, ∗∗p-value ≤ 0.01. A one-way ANOVA test was used for statistical analysis.
entry was assessed via immunofluorescence detection of the viral
capsid protein ORF65. Actin-phalloidin and DAPI staining were
included in order to visualize the subcellular localization of the
viral particles. Regardless of the treatment utilized, there was
no significant difference in the number of capsids observed at
30 min (binding), 60 min (entry), or 120 min (transport to the
nucleus) post-infection (Figure 4C). Collectively, the data from
these experiments suggests that neither chemical nor CO-based
inhibition of TLR4 signaling has a measurable impact on the
initial stages of KSHV infection of iLEC that culminate in nuclear
delivery of the viral genome. To further substantiate this result,
we next employed the viral polymerase inhibitor foscarnet (FOS)
to evaluate intracellular levels of viral DNA in the absence of
viral replication, thus allowing for measurement of only input
viral genomes. iLEC were pretreated for 2 h with CLI-095 or for
10 min with CORM-2 and then treated with FOS for 1 h prior
to infection. The cells were subsequently infected with KSHV,
collected at intervals from 2 to 8 hpi and analyzed via qPCR
for viral DNA content (Figure 4D). As expected, treatment with
FOS blocked viral DNA replication. Importantly, in the presence
of FOS, similar amounts of viral DNA were present at 2 hpi in
CO, CLI-095 and vehicle-treated cells. In agreement with results
shown in Figures 2, 3, CO and CLI-095 treatment in the absence
of FOS increased the number of intracellular viral genomes
detected at later time points (6 and 8 hpi). Taken together, our
data suggest that inhibition of TLR4 activation benefits a phase
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FIGURE 4 | TLR4 inhibition via CO or CLI-095 does not affect virus binding, entry or genome delivery to the nucleus. qPCR for KSHV genome copies in
(A) the cytoplasmic fraction and (B) the nuclear fraction of iLEC pretreated with 3 µM CLI-095 (pale gray) for 2 h or 10 µM CORM-2 (light gray) for 10 min and then
infected with KSHV-BAC16. DMSO (dark gray) was used as a vehicle control. KSHV genome copies are represented as number of genomes per 100 ng DNA. Data
are expressed as the mean ± SEM (n = 3). (C) Immunofluorescent analysis of iLEC infected with KSHV-BAC16 for 30, 60, or 120 min. Expression of ORF65 (green),
Actin (red), and DAPI (blue) are shown. Single left panel: Uninfected cells (mock). Top three panels: DMSO-treated iLEC. Middle three panels: CLI-095 treated iLEC.
Bottom three panels: CORM-2-treated iLEC. Images were captured at 60× magnification (scale bar = 30 µm). (D) qPCR for KSHV genome copies in iLEC
pretreated with 3 µM CLI-095 for 2 h or 10 µM CORM-2 for 10 min and then infected with KSHV-BAC16 for up to 8 h in the presence or absence of 400 µM
Foscarnet (+FOS). DMSO was used as a vehicle control. KSHV genome copies (2–8 hpi) are represented as number of genomes per 100 ng DNA. Data are
expressed as the mean ± SEM (n = 3). A one-way ANOVA test was used for statistical analysis. ∗p-value ≤ 0.05, ∗∗p-value ≤ 0.01.
of KSHV infection that occurs following viral genome delivery to
the nucleus.
DISCUSSION
Kaposi sarcoma herpesvirus infection of endothelial cells results
in robust expression of the inducible isoform of heme oxygenase,
HO-1, both in vivo and in vitro (McAllister et al., 2004; Botto
et al., 2015). In vitro, HO-1 appears to be upregulated in a
biphasic manner by two distinct mechanisms. The first of these
is operational at early times after de novo infection, and the
second comes into play once the virus has established latency
(Botto et al., 2015). In the present study we investigated the
consequences of HO-1 induction during the early stages of de
novo KSHV infection. KSHV infection of target cells is known
to trigger activation of host signaling pathways that promote
viral entry and delivery of viral DNA to the nucleus (Chandran,
2010). At the same time, the infection process activates a variety
of host innate immune responses, including the TLR4 signaling
pathway, to induce an antiviral state (Lagos et al., 2008). KSHV
encodes several proteins and microRNAs that have been shown to
subvert the antiviral innate immune response. In many instances,
the host proteins targeted by particular viral factors have been
identified, and this is particularly true in the context of innate
immune evasion mechanisms adopted by KSHV to evade or
manipulate the IFN response (Sathish and Yuan, 2011; Brulois
and Jung, 2014; Lee et al., 2015). While the specific viral factor(s)
that transiently upregulates HO-1 to facilitate CO-mediated
suppression of the TLR4 pathway remains to be identified, our
data predict that a virion component is responsible, thereby
allowing the inhibition of innate host defenses immediately upon
infection. This method of HO-1 induction is both distinct from
and independent of the KSHV-dependent induction of HO-1
during latency, for which the mechanism has been previously
defined (Gjyshi et al., 2014; Botto et al., 2015). This separation
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suggests that HO-1 may play temporally and functionally distinct
roles during the KSHV life cycle, first by facilitating the
initial infection event and later participating in the successful
establishment of viral latency.
In this report, we describe a novel mechanism of TLR4
inhibition in KSHV-infected LEC that is mediated by HO-1
and CO, an endogenous gasotransmitter produced through the
catabolism of heme. Shortly after de novo infection, KSHV
activates both the host TLR4 signaling pathway and expression of
HO-1, and then the CO generated as a result of KSHV-induced
HO-1 activity downmodulates TLR4 signaling and promotes
KSHV infection. We found that when KSHV-infected LEC are
pretreated with either a TLR4 inhibitor or exogenous CO, they
support increased viral gene expression and generate higher
genome copy numbers. Moreover, cells subjected to elevated
levels of CO express reduced levels of IL-1β and IFNβ, two
antiviral cytokines associated with TLR4 activation. Importantly,
in response to early HO-1 induction, KSHV-infected cells contain
measurably higher levels of intracellular CO, indicating that
HO-1 activity in infected cells can indeed increase endogenous
CO levels. In support of this conclusion, cells pretreated with
an inhibitor of HO-1 enzyme activity are less permissive to
KSHV infection, produce higher levels of inflammatory cytokines
and contain less CO. Collectively, these data suggest that
HO-1-activity liberates CO from heme at levels sufficient to
inhibit the TLR4-activated antiviral response to de novo KSHV
infection.
We attempted to identify the stages of KSHV infection that are
impacted by CO-mediated suppression of TLR4 signaling. TLR4
signaling is known to activate a series of pathways that culminate
in the transcription of genes encoding inflammatory cytokines
and chemokines, as well as type I IFN. IFNβ secretion from
infected cells results in the activation of IFN-stimulated genes
(ISGs) that initiate an antiviral program capable of acting on
both infected cells and uninfected neighboring cells (Schoggins
and Rice, 2011; Schneider et al., 2014). Certain antiviral ISGs,
including MDA5, RIG-1, and TRIM proteins, are involved in
the amplification and regulation of the IFN response (Schoggins
and Rice, 2011). Others such as Mx, OAS, RNaseL, APOBEC3,
and PKR are involved in antiviral mechanisms that interfere
with the virus life cycle (Schoggins and Rice, 2011). Interestingly,
we observed no significant difference in the number of KSHV
virions able to bind, enter, or reach the nucleus of infected
EC. In contrast, we detected significant differences in viral gene
expression and genome copies at later times post-infection.
One possible explanation is that CO-mediated inhibition of
the TLR4-triggered antiviral response facilitates a phase of
KSHV infection that occurs following viral genome delivery
to the nucleus, potentially by impacting expression of ISGs
acting on either the target and/or neighboring cells. Yet another
possibility comes from recent studies that have identified host
innate immune pathways initiated upon delivery of KSHV
dsDNA genomes to the nucleus. These include activation of
the DNA Damage Response (DDR) (Singh et al., 2014) as
well as formation of nuclear inflammasomes, the latter of
which is mediated by the interferon gamma-inducible protein
16 (IFI16) (Kerur et al., 2011). Interestingly, DDR signaling
is important for successful establishment and maintenance of
KSHV latency (Singh et al., 2014), and the same may be true
for IFI16-mediated inflammasome induction. Alternately, if the
IFI16 inflammasome represents an effective antiviral response,
it is possible that KSHV has evolved a strategy to evade
or usurp this mechanism. In this scenario, TLR4 represents
another arm of the innate immune response that is induced
during the early stages of KSHV infection, and KSHV usurps
HO-1 to inhibit TLR4 signaling via a CO-mediated mechanism.
Other studies have shown that KSHV binding to endothelial
cells results in rapid activation of the TLR4 pathway (Lagos
et al., 2008), and induction of NRF-2 (Gjyshi et al., 2014), the
latter mechanism being essential for establishment of de novo
infection. We can therefore envision a model whereby NRF-2
activation of HO-1 enzyme activity allows for production of the
gasotransmitter CO, which in turn inhibits TLR4 signaling to
facilitate establishment of KSHV infection after nuclear genome
delivery. HO-1 homeostasis is then rapidly reestablished, likely
via the action of the HO-1 repressor BACH-1. HO-1 is induced
once again after the establishment of latency, due at least in
part to KSHV miR-K12-11, which targets BACH-1 (Botto et al.,
2015).
It is not unprecedented for herpesviruses to subvert host
proteins to evade TLR4. For example, EBV induces the host
microRNA miR-21 (Mrazek et al., 2007), which indirectly
attenuates TLR4 signaling via the host protein PDCD4 (Sheedy
et al., 2009). KSHV subversion of the TLR4 pathway has also
been previously reported. For example, Lagos et al. (2008)
demonstrated that ectopic expression of the viral lytic proteins
vIRF1 and vGPCR leads to downregulation of both TLR4 mRNA
and signal activation, while other groups have shown that the
viral RTA decreases TLR4 protein levels (Bussey et al., 2014)
and is able to further inhibit TLR signaling by degrading the
TLR4/TLR3 adaptor TRIF (Ahmad et al., 2011). Given TLR4’s
importance in innate immunity, it is not surprising that KSHV
has evolved more than one way to limit the activation of this
pathway and its downstream consequences. Interestingly, the
mechanism we define herein is novel in that TLR4 signaling is
attenuated indirectly by the virus via the action of yet another
host protein, HO-1.
Heme oxygenase-1 and the heme metabolite CO have been
shown to inhibit TLR4 signaling to reduce cytokine-driven
inflammatory outcomes and protect cells against oxidative stress
(Liu et al., 2002; Otterbein et al., 2005; Nakahira et al., 2006;
Tsiftsoglou et al., 2006; Lin et al., 2009; Wang et al., 2009; Ruan
et al., 2014; Xue and Habtezion, 2014). In addition to TLR4, CO
also inhibits the activation of TLR2, TLR5, and TLR9 (Nakahira
et al., 2006). However, among of this subset of TLRs, only TLR4
and TLR9, are directly activated by KSHV infection (Perry and
Compton, 2006; Lagos et al., 2008). Whether the HO-1/CO axis
acts as an endogenous inhibitor of TLR9 activation in the context
of KSHV remains to be determined.
In addition to KS, HO-1 is highly induced in several
other cancers, where it has been shown to contribute to
tumor progression by promoting cell proliferation, angiogenesis,
cytoprotection, and resistance to chemotherapy (Ryter and
Tyrrell, 2000; Ryter et al., 2006; Lanceta et al., 2015).
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The current study, combined with our previous work
demonstrating that KSHV-enhanced HO-1 activity promotes
the growth of KSHV-infected EC, indicates that HO-1 can
positively influence both the KSHV infection process and
virus-driven tumorigenic mechanisms (McAllister et al., 2004).
Here we show for the first time that HO-1 induction by
KSHV facilitates viral infection by attenuating critical antiviral
mechanisms. Identification of a dual role for HO-1 in promoting
KSHV infection and tumorigenesis in endothelial cells further
establishes its validity as a therapeutic target for KS.
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